Skip to search formSkip to main contentSkip to account menu

semaglutide

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Glucagon-Like Peptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity
Abstract Background and Aims Epicardial adipose tissue (EAT), the visceral fat depot of the heart, is a modifiable cardio… 
2020
2020
Semaglutide once weekly in people with type 2 diabetes: Real‐world analysis of the Canadian LMC diabetes registry (SPARE study)
To investigate real‐world short‐term clinical outcomes in adults with type 2 diabetes (T2D) who initiated semaglutide in a… 
2019
2019
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
Introduction The PIONEER trial programme showed that, after 52 weeks, the novel oral glucagon-like peptide-1 (GLP-1) analogue… 
Highly Cited
2018
Highly Cited
2018
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation of a glucagon‐like peptide‐1 receptor… 
Review
2018
Review
2018
Oral semaglutide for the treatment of type 2 diabetes
ABSTRACT Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists are highly potent antihyperglycemic drugs that impose… 
Review
2017
Review
2017
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Review
2017
Review
2017
Novel Diabetes Drugs and the Cardiovascular Specialist.
Highly Cited
2017
Highly Cited
2017
Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial
Aims/hypothesisSemaglutide is a glucagon-like peptide-1 analogue in development for the treatment of type 2 diabetes. Its effects… 
Review
2017
Review
2017
SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
Diabetic kidney disease not only has become the leading cause for ESRD worldwide but also, highly contributes to increased… 
Review
2014
Review
2014
GLP‐1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents
More than 26 million people in the United States have type 2 diabetes mellitus (T2D). Many treatment options exist, but achieving… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)